These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16337994)

  • 1. Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
    Amikura T; Sekine M; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Nishino K; Haino K; Tanaka K;
    Gynecol Oncol; 2006 Feb; 100(2):365-71. PubMed ID: 16337994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
    Eachkoti R; Hussain I; Afroze D; Aejazaziz S; Jan M; Shah ZA; Das BC; Siddiqi MA
    Cancer Lett; 2007 Apr; 248(2):308-20. PubMed ID: 16996204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
    Berchuck A; Heron KA; Carney ME; Lancaster JM; Fraser EG; Vinson VL; Deffenbaugh AM; Miron A; Marks JR; Futreal PA; Frank TS
    Clin Cancer Res; 1998 Oct; 4(10):2433-7. PubMed ID: 9796975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
    Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
    Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
    Manié E; Vincent-Salomon A; Lehmann-Che J; Pierron G; Turpin E; Warcoin M; Gruel N; Lebigot I; Sastre-Garau X; Lidereau R; Remenieras A; Feunteun J; Delattre O; de Thé H; Stoppa-Lyonnet D; Stern MH
    Cancer Res; 2009 Jan; 69(2):663-71. PubMed ID: 19147582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
    Buller RE; Lallas TA; Shahin MS; Sood AK; Hatterman-Zogg M; Anderson B; Sorosky JI; Kirby PA
    Clin Cancer Res; 2001 Apr; 7(4):831-8. PubMed ID: 11309330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
    Aghmesheh M; Nesland JM; Kaern J; Dorum A; Edwards L; Byth K; Friedlander M; Jackson P; Tucker KM; Russell PJ
    Gynecol Oncol; 2004 Dec; 95(3):430-6. PubMed ID: 15581943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
    Zheng L; Wang F; Qian C; Neumann RM; Cheville JC; Tindall DJ; Liu W
    Hum Mutat; 2006 Oct; 27(10):1062-3. PubMed ID: 16941491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational analysis of the estrogen receptor-alpha gene in familial ovarian cancer.
    Wu HJ; Sekine M; Kashima K; Hirai Y; Hatae M; Kobayashi I; Obata K; Enomoto T; Umesaki N; Ushijima K; Tanaka K;
    J Obstet Gynaecol Res; 2005 Oct; 31(5):375-83. PubMed ID: 16176503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
    Birgisdottir V; Stefansson OA; Bodvarsdottir SK; Hilmarsdottir H; Jonasson JG; Eyfjord JE
    Breast Cancer Res; 2006; 8(4):R38. PubMed ID: 16846527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis.
    Reedy MB; Hang T; Gallion H; Arnold S; Smith SA
    Gynecol Oncol; 2001 Jun; 81(3):441-6. PubMed ID: 11371136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.
    Brozek I; Ochman K; Debniak J; Morzuch L; Ratajska M; Stepnowska M; Stukan M; Emerich J; Limon J
    Gynecol Oncol; 2008 Feb; 108(2):433-7. PubMed ID: 17997147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP).
    Geisler JP; Hatterman-Zogg MA; Rathe JA; Lallas TA; Kirby P; Buller RE
    Hum Mutat; 2001 Oct; 18(4):337-44. PubMed ID: 11668617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1.
    Aida H; Takakuwa K; Nagata H; Tsuneki I; Takano M; Tsuji S; Takahashi T; Sonoda T; Hatae M; Takahashi K; Hasegawa K; Mizunuma H; Toyoda N; Kamata H; Torii Y; Saito N; Tanaka K; Yakushiji M; Araki T; Tanaka K
    Clin Cancer Res; 1998 Jan; 4(1):235-40. PubMed ID: 9516977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. G:C > A:T mutations and potential epigenetic regulation of p53 in breast cancer.
    Kouidou S; Malousi A; Kyventidis A; Fragou A; Maglaveras N
    Breast Cancer Res Treat; 2007 Dec; 106(3):351-60. PubMed ID: 17505880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
    Rubin SC; Benjamin I; Behbakht K; Takahashi H; Morgan MA; LiVolsi VA; Berchuck A; Muto MG; Garber JE; Weber BL; Lynch HT; Boyd J
    N Engl J Med; 1996 Nov; 335(19):1413-6. PubMed ID: 8875917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases.
    Ramus SJ; Pharoah PD; Harrington P; Pye C; Werness B; Bobrow L; Ayhan A; Wells D; Fishman A; Gore M; DiCioccio RA; Piver MS; Whittemore AS; Ponder BA; Gayther SA
    Cancer Res; 2003 Jan; 63(2):417-23. PubMed ID: 12543797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
    Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
    Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
    Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J
    Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.